Format

Send to

Choose Destination
Tuberculosis (Edinb). 2014 Dec;94(6):708-11. doi: 10.1016/j.tube.2014.09.001. Epub 2014 Sep 19.

Thioridazine for treatment of tuberculosis: promises and pitfalls.

Author information

1
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ndutta1@jhmi.edu.
2
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: petros@jhmi.edu.

Abstract

The articles by De Knegt et al. and Singh et al. in a recent issue of this Journal address one of the current debates regarding the potential role of thioridazine in the treatment of tuberculosis. This commentary presents a summary of the available evidence, and, emphasizing the need for further research, asks the question: "How far can we go in repurposing thioridazine?"

KEYWORDS:

Adjunctive therapy; Animal model; Efflux pump inhibitor; Latent TB; Mycobacterium tuberculosis; Thioridazine

PMID:
25293998
DOI:
10.1016/j.tube.2014.09.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center